About Dr. Wang Jialei
Dr. Wang Jialei (王佳蔓) is a Professor, Doctoral Supervisor, and one of China's leading medical oncologists specializing in breast cancer and lung cancer systemic therapy, based at the Department of Medical Oncology, Fudan University Shanghai Cancer Center (FUSCC). With extensive clinical and research expertise in the pharmacological management of advanced and metastatic breast cancer — including hormone receptor-positive, HER2-positive, and triple-negative subtypes — and in the systemic treatment of non-small cell lung cancer (NSCLC) with targeted therapy and immunotherapy, Dr. Wang is recognized as a senior authority in precision medical oncology at China's foremost dedicated cancer center.
The systemic treatment of breast cancer and lung cancer has been transformed over the past decade by the development of molecularly targeted therapies and immune checkpoint inhibitors that have dramatically improved outcomes for patients with specific molecular subtypes. For breast cancer, the introduction of CDK4/6 inhibitors for hormone receptor-positive metastatic disease, antibody-drug conjugates (trastuzumab deruxtecan, sacituzumab govitecan) for HER2-positive and triple-negative disease, PARP inhibitors for BRCA-mutant disease, and PI3K inhibitors for PIK3CA-mutant disease has created a complex and rapidly evolving treatment landscape that requires specialist expertise to navigate optimally. For NSCLC, the identification of actionable driver mutations — EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS G12C — and the development of highly effective targeted therapies for each has made molecular profiling and targeted therapy selection the cornerstone of NSCLC management. Dr. Wang's clinical practice at FUSCC — supported by the center's comprehensive molecular profiling capabilities and active clinical trials program — provides international patients with access to the most current evidence-based systemic therapy for breast cancer and NSCLC.
Hospital Affiliation: Department of Medical Oncology, Fudan University Shanghai Cancer Center
Fudan University Shanghai Cancer Center (FUSCC) is China's foremost dedicated cancer center, managing tens of thousands of new cancer cases annually. Its Department of Medical Oncology is one of the largest and most academically productive medical oncology programs in China, with dedicated disease-specific teams for breast cancer, lung cancer, gastrointestinal cancer, gynecological cancer, and other major tumor types. The department's clinical trials program is one of the most active in China, providing access to investigational targeted agents, immunotherapy combinations, and antibody-drug conjugates across all major tumor types. Its molecular profiling laboratory provides comprehensive NGS tumor profiling, ctDNA liquid biopsy, and the full range of predictive biomarker assessments to guide treatment selection.
Clinical Specialties: What Dr. Wang Jialei Treats
- Hormone receptor-positive (HR+) / HER2-negative breast cancer — first-line and subsequent-line endocrine therapy with aromatase inhibitors, fulvestrant, and tamoxifen; CDK4/6 inhibitor combinations (palbociclib, ribociclib, abemaciclib) for metastatic HR+/HER2- breast cancer; PI3K inhibitor (alpelisib) for PIK3CA-mutant disease; mTOR inhibitor (everolimus) combinations; PARP inhibitors (olaparib, niraparib) for BRCA1/2-mutant metastatic breast cancer; ESR1 mutation monitoring by liquid biopsy for endocrine resistance; sacituzumab govitecan for heavily pretreated HR+ metastatic breast cancer; coordination with breast surgery and radiation oncology for neoadjuvant and adjuvant treatment
- HER2-positive breast cancer — first-line trastuzumab/pertuzumab/taxane for metastatic HER2+ breast cancer; T-DM1 (ado-trastuzumab emtansine) for second-line treatment; trastuzumab deruxtecan (T-DXd) for previously treated HER2+ metastatic breast cancer; lapatinib and neratinib combinations; tucatinib/trastuzumab/capecitabine for HER2+ breast cancer with brain metastases; neoadjuvant dual HER2 blockade with pertuzumab and trastuzumab; post-neoadjuvant T-DM1 for residual disease; coordination with breast surgery and radiation oncology
- Triple-negative breast cancer (TNBC) — neoadjuvant chemotherapy with carboplatin-containing regimens; pembrolizumab plus chemotherapy for PD-L1-positive metastatic TNBC; sacituzumab govitecan for previously treated metastatic TNBC; PARP inhibitors for BRCA-mutant TNBC; olaparib adjuvant therapy for high-risk BRCA-mutant early TNBC; capecitabine adjuvant therapy for residual disease after neoadjuvant chemotherapy
- EGFR-mutant non-small cell lung cancer (NSCLC) — first-line osimertinib for EGFR exon 19 deletion and L858R-mutant NSCLC; management of T790M-mediated acquired resistance with osimertinib; identification and management of non-T790M resistance mechanisms including MET amplification, HER2 amplification, and histological transformation; amivantamab and lazertinib for post-osimertinib progression; EGFR exon 20 insertion management with amivantamab and mobocertinib
- ALK-rearranged and other driver-mutant NSCLC — first-line alectinib or brigatinib for ALK-rearranged NSCLC; lorlatinib for ALK-rearranged NSCLC with brain metastases or after second-generation ALK inhibitor failure; ROS1-rearranged NSCLC management with crizotinib and entrectinib; RET-rearranged NSCLC with selpercatinib and pralsetinib; MET exon 14-skipping NSCLC with tepotinib and capmatinib; KRAS G12C-mutant NSCLC with sotorasib and adagrasib; NTRK-rearranged NSCLC with larotrectinib and entrectinib
- Immunotherapy for NSCLC — pembrolizumab monotherapy for high PD-L1-expressing (TPS ≥50%) advanced NSCLC; pembrolizumab plus chemotherapy for PD-L1-unselected advanced NSCLC; atezolizumab and nivolumab combinations; durvalumab consolidation after concurrent chemoradiotherapy for unresectable stage III NSCLC; immunotherapy toxicity management including immune-related adverse events (irAEs)
- Liquid biopsy and ctDNA monitoring — ctDNA-based detection of acquired resistance mutations (T790M, ALK resistance mutations, ESR1 mutations) to guide treatment switching; ctDNA monitoring for treatment response assessment and minimal residual disease detection; comprehensive liquid biopsy NGS for patients with insufficient tissue for molecular profiling
Why International Patients Choose Dr. Wang Jialei and FUSCC
International patients seek medical oncology consultation with Dr. Wang Jialei and FUSCC for reasons that reflect both the clinical depth of her expertise in breast cancer and NSCLC systemic therapy and the comprehensive molecular profiling and clinical trials infrastructure available at China's foremost cancer center.
For patients with metastatic breast cancer who have progressed on standard therapies, Dr. Wang's expertise in the full range of approved and investigational agents — including antibody-drug conjugates such as trastuzumab deruxtecan and sacituzumab govitecan, PARP inhibitors for BRCA-mutant disease, and PI3K inhibitors for PIK3CA-mutant disease — provides access to treatment options that may not be available or affordable at the patient's home institution. The cost of targeted therapies and antibody-drug conjugates at FUSCC is substantially below that of equivalent treatment in Western healthcare systems.
For patients with NSCLC who have not undergone comprehensive molecular profiling — or whose profiling has not identified all actionable alterations — FUSCC's comprehensive NGS tumor profiling and liquid biopsy capabilities provide the molecular characterization needed to identify targeted therapy options that may not have been previously considered. For patients with acquired resistance to first-line targeted therapy, Dr. Wang's expertise in resistance mechanism identification and subsequent therapy selection provides a systematic approach to treatment optimization that is available at only a small number of centers in China.
What to Expect at Your Consultation
Consultations with Dr. Wang Jialei at FUSCC arranged through CMCS begin with a comprehensive review of all prior oncological records — including pathology and molecular profiling results, staging imaging, tumor marker trends, prior systemic therapy records, and relevant laboratory investigations. CMCS will arrange certified translation of all medical records in advance of the consultation. Dr. Wang will assess the tumor subtype and molecular profile, evaluate current and prior treatment, outline the recommended systemic therapy strategy with detailed rationale, assess clinical trial eligibility, and coordinate multidisciplinary tumor board review. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Wang's team and the patient's home oncologist for continuity of care.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking medical oncology consultation with Dr. Wang Jialei at Fudan University Shanghai Cancer Center. Our services include priority consultation scheduling, certified medical record and pathology report translation, coordination of molecular profiling and staging investigations, on-site interpretation, systemic therapy administration coordination, clinical trial eligibility assessment, and written English-language reporting of all findings and recommendations.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 Kommentare